for years, the best available evidence has suggested targeting K>3.5 (not the traditional target of K>4)
maybe this study will get us a step closer to implementing K>3.5, I'm afraid the K>4 dogma is so entrenched we're 20 yrs from real change...
(#1/2)
https://t.co/pj9pJBXUgI
Incidence of T-Cell Lymphoma in recipients of CAR-T's: 12/7,946 pts treated (0.15%). Very rare.
Incidence of myeloid malignancies (MDS etc) in those who got cilta-cel: 10/97 patients treated (10%). Quite common-more than expected.
Context matters. Lets not minimize.
Nothing but a couple New England sports legends throwing out the opening pitches at Fenway 🏉🏒⚾️
Thank you @RedSox and great meeting @NHLBruins star and former rugby player Milan Lucic
🎉🎊🎉Finally out!🔥🔥🔥
HemeOncBuddy app on most important clinical trials in hematology and oncology!
Please spread the word! 🗣📢
https://t.co/jDSGMXomwO
*only ~100 trials for now. Hope I can double the number of trials in next couple months.
#ASH#ASCO#medtwitter